Seventeen out of 19 PV patients (89.5%), 11 out of 21 ET patients (52.4%),and 2 out of 5 PMF patients (40.0%) revealed JAK2 V617F mutations. The gene discussed is JAK2; the disease is essential thrombocythemia.